BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

被引：0
|
作者：
Asano, E. [1 ]
Nita, M. [1 ]
Moellmann-Coelho, A. [2 ]
Rached, R. [1 ]
Donato, B. [3 ]
Rahal, E. [1 ]
机构：
[1] Bristol Myers Squibb SA, Sao Paulo, Brazil
[2] Inst Nacl Canc INCA, Rio De Janeiro, Brazil
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74285-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A262 / A262
页数：1
相关论文
共 50 条
  • [21] Dasatinib therapy of patients with chronic myeloid leukemia resistant to imatinib therapy
    Khoroshko, N. D.
    Vinogradova, O. Yu.
    Turkina, A. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2008, 53 (03): : 29 - 34
  • [22] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [23] Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: Impact and fate of imatinib-resistant clones in dasatinib-treated patients.
    Branford, S
    Hughes, T
    Nicoll, J
    Paquette, R
    Bleickardt, E
    Sawyers, C
    Shah, N
    BLOOD, 2005, 106 (11) : 132A - 132A
  • [24] Five-year follow-up of patients with imatinib-resistant or - intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    Guilhot, F.
    Brummendorf, T. H.
    Chen, A. C.
    Healey, D.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ohyashiki, Kazuma
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6181 - 6186
  • [26] Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
    Lee, Jeong-Ok
    Kim, Inho
    Chung, Joo-Seop
    Kim, Yeo-Kyeoung
    Yhim, Ho-Young
    Kim, Dae-Young
    Do, Young-Rok
    Seong, Chu-Myong
    Nam, Seung-Hyun
    Kim, Sung-Hyun
    Lee, Jae-Hoon
    Park, Jinny
    Kim, Jin Seok
    Min, Yoo-Hong
    Sohn, Sang Kyun
    Joo, Young Don
    Bae, Sung-Hwa
    Oh, Sukjoong
    Zang, Dae Young
    Lee, Hong Ghi
    Yoon, Sung-Soo
    Park, Seonyang
    BLOOD, 2012, 120 (21)
  • [27] COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB 800 MG IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN
    Ramirez de Arellano, A.
    Sbarigia, U.
    Taylor, M. J.
    Martin, P.
    Restovic, G.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [28] Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia
    Assouline, Sarit
    Laneuville, Pierre
    Gambacorti-Passerini, Carlo
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24): : 2623 - 2624
  • [29] Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
    Cortes, Jorge
    Rousselot, Philippe
    Kim, Dong-Wook
    Ritchie, Ellen
    Hamerschlak, Nelson
    Coutre, Steven
    Hochhaus, Andreas
    Guilhot, Francois
    Saglio, Giuseppe
    Apperley, Jane
    Ottmann, Oliver
    Shah, Neil
    Erben, Philipp
    Branford, Susan
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Baccarani, Michele
    BLOOD, 2007, 109 (08) : 3207 - 3213
  • [30] BENEFITS/RISKS OF DASATINIB THERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA: PHYSICIAN'S AND PATIENT'S
    Ionova, T.
    Nikitina, T.
    Gritsenko, T.
    Ivanova, V.
    Kuchma, G.
    Shnaider, T.
    Sannikova, I.
    Fedorenko, D.
    Kurbatova, K.
    HAEMATOLOGICA, 2013, 98 : 559 - 559
12345